Assembly Bio reports Q3 net loss of $9.6M; positive Phase 1a data for ABI-5366

ASSEMBLY BIOSCIENCES, INC.

2024-Q3 EPS reported -$5.12 revenue$21,163,000

Net loss of $9.6M ($1.51/share) vs $14.4M ($3.29/share) in Q3 2023; revenue of $6.8M from Gilead collaboration.
Cash $95.0M as of Sept 30, 2024, projected to fund operations into Q1 2026.
Positive Phase 1a interim data for ABI-5366 (HSV) supports once-weekly and once-monthly oral dosing; Phase 1b initiated.
Phase 1b trial for ABI-4334 (HBV) ongoing, interim data expected by end of 2024.
ABI-1179 and ABI-6250 on track to enter clinic by end of 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.